All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Leishmaniases are a group of diseases caused by obligatory intracellular protozoan parasites of the genus *Leishmania*. Among the species of *Leishmania*, *Leishmania infantum* is mostly responsible for canine leishmaniasis (CanL), although it also causes sporadic cases of human visceral leishmaniasis (VL), and rare cases of cutaneous and muco-cutaneous leishmaniasis (CL and MCL) throughout the Mediterranean basin \[[@pntd.0004303.ref001]\]. Transmission to humans is caused by the bite of infected phlebotomine sandflies, and dogs are considered to be the principal domestic reservoir. In France, the parasite is currently only endemic in the south of France, along the Mediterranean coast, where several foci have been clearly identified: Pyrénées-Orientales, Cévennes (CE), Provence (P), Alpes-Maritimes (AM) and Corsica (CO) \[[@pntd.0004303.ref002]\]. In the Provence-Alpes-Côtes d'Azur (PACA) region, which comprises the AM and P endemic areas, transmission has been reported for 100 years \[[@pntd.0004303.ref003],[@pntd.0004303.ref004]\]. The two cities of Nice and Marseille, which are located 150 km apart, and their surroundings concentrate the greatest number of French autochthonous leishmaniasis cases \[[@pntd.0004303.ref002],[@pntd.0004303.ref005]\]. Although the same species of *L*. *infantum* (primarily zymodeme MON-1), the same predominant vector (*Phlebotomus perniciosus*) and the same and unique reservoir (dog) are found in both regions, the transmission environment of VL is heterogeneous in these two foci \[[@pntd.0004303.ref005]\]. Disease transmission in Nice and the surrounding area is associated with scattered habitation and mixed forest in the foothills \[[@pntd.0004303.ref005]\]. In contrast, around Marseille, VL transmission is associated with an urban environment \[[@pntd.0004303.ref005]\]. Regarding the main vector; *Phlebotomus pernicious*; the population is quite homogeneous and belongs mainly to the same haplogroup (for 88% pern01) in Provence, France \[[@pntd.0004303.ref006]\]. The isolates of *L*. *infantum* from AM and P endemic foci have been characterized using Multi-Locus Enzyme Electrophoresis (MLEE), which is the current reference method. However, MLEE based analyses are limited at the intrinsic level of polymorphisms. Thus, differentiating between isolates in PACA region is impossible using the MLEE method \[[@pntd.0004303.ref007]\]. Epidemiological studies on *L*. *infantum* require the use of highly discriminative techniques that can differentiate between MON-1 strains. Multi-Locus Microsatellite Typing (MLMT) has been shown to be a powerful tool for population genetics and epidemiological studies of *Leishmania spp*. \[[@pntd.0004303.ref008]\]. This tool has been already applied to genotype *L*. *infantum* isolates from healthy blood donors, sandflies, dogs and human patients in Southern France \[[@pntd.0004303.ref009]\]. Genetic differentiations were evidenced between asymptomatic carrier strains and non-asymptomatic carrier strains and especially between asymptomatic carrier and HIV+ populations \[[@pntd.0004303.ref009]\]. However, due to the weak sample size, these results must be confirmed on a larger sample set \[[@pntd.0004303.ref009]\].

In the current study, microsatellite markers were used to analyze the genetic diversity of *L*. *infantum* parasites from Southeast France, with a focus on the PACA region. We assessed an extensive panel of isolates from an extended time period (1978--2011), from the two endemic regions of AM and P. The geographical and temporal distributions of genotypes were examined. The microsatellite profiles were used to assess relapse and re-infection among patients as well as the association between genotype and the various clinical forms of the disease.

Materials and Methods {#sec002}
=====================

Parasites {#sec003}
---------

The *L*. *infantum* isolates used in this study were obtained from the collection of the Centre National de Référence des *Leishmania* (*Leishmania* collection, BRC-Leish, Montpellier, France, BioBank N° BB-0033-00052). All human and animal samples had been isolated from patients and animals as part of routine diagnosis and treatment with no unnecessary invasive procedures. A total of 270 *L*. *infantum* isolates from the south of France were included in this study ([Table 1](#pntd.0004303.t001){ref-type="table"}). This panel included 247 human isolates from 239 patients (four patients harbored more than one isolate), 20 from CanL, one from feline leishmaniasis and two from sandflies. Among the 239 patients, there were 154 adult VL cases, 58 infant VL cases, 13 CL cases (five infants, seven adults and one unknown), three MCL adult cases, nine asymptomatic carriers (in adults) and two unknown cases (one adult and one unknown). Among the 247 human samples, 139 were isolated from immunocompetent patients, 95 from immunocompromised HIV+ patients, 11 from immunocompromised patients other than HIV+ (e.g., renal transplantation, lymphoma, auto immunity disease and cancer) and two from unknown cases. The location of isolates based on their position relative to the Vars River ([S1 Table](#pntd.0004303.s001){ref-type="supplementary-material"}) was used for genetic differentiation analysis.
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###### Designation and characteristics of *Leishmania infantum* isolates used in this study.

![](pntd.0004303.t001){#pntd.0004303.t001g}

  Endemic area   Patients      Sample WHO code         Y      C F / H   HIV status   Zymo      G     P     Sub-Pop A   Sub-Pop A   Sub-Pop B
  -------------- ------------- ----------------------- ------ --------- ------------ --------- ----- ----- ----------- ----------- -----------
  P              Patient 1     MHOM/FR/94/LPM135       1994   VL        HIV          MON-1     1     A     6           3           
  AM             Patient 2     MHOM/FR/90/LPN63        1990   VL        HIV          MON-24    2     A     6           3           
  AM             Patient 3     MHOM/FR/2002/LPN202     2002   IVL                    MON-1     3     A     4           1           
  P                            MCAN/FR/2000/LPM206     2000   CanL                   MON-1     4     A     4           1           
  AM             Patient 4     MHOM/FR/2003/LPN212     2003   VL        HIV          MON-1     4     A     4           1           
  AM             Patient 4     MHOM/FR/2004/LPN243     2004   RVL       HIV          MON-1     4     A     4           1           
  AM             Patient 5     MHOM/FR/90/LPN67        1990   VL        HIV          MON-1     5     A     4           1           
  AM             Patient 6     MHOM/FR/96/LPN126       1996   IVL                    MON-1     6     A     4/3         1           
  P              Patient 7     MHOM/FR/93/LPM110       1993   VL        HIV          MON-11    7     A     4/6         1/3         
  AM             Patient 8     MHOM/FR/90/LPN62        1990   VL                     MON-1     8     B                             1
  AM             Patient 9     MHOM/FR/98/LPN163       1998   IVL                    MON-1     9     B                             1
  P              Patient 10    MHOM/FR/96/LPM150       1996   VL        HIV          MON-1     10    A     4/5         1/2         
  AM             Patient 11    MHOM/FR/2001/LPN192     2001   IVL                    MON-1     11    B/A                           
  CE                           MCAN/FR/2006/LPN278     2006   CanL                   MON-1     12    A     4/5         1/2         
  P              Patient 12    MHOM/FR/97/LPM180       1997   VL        HIV          MON-1     13    A     5           2           
  P                            MCAN/FR/2000/LPM207     2000   CanL                   MON-1     13    A     5           2           
  P              Patient 13    MHOM/FR/2009/LPM262     2009   VL        HIV          MON-1     13    A     5           2           
  P              Patient 14    MHOM/FR/2000/LPM197     2000   VL        HIV          MON-1     14    A     5           2           
  AM             Patient 15    MHOM/FR/97/LPN161       1997   CL                     MON-1     15    A     1           4           
  CO             Patient 16    MHOM/FR/97/LPN154       1997   VL                     MON-1     16    A     6           3           
  P              Patient 17    MHOM/FR/2002/LPM225     2002   VL        HIV          MON-1     17    A     5           2           
  P              Patient 18    MHOM/FR/2002/LPM215     2002   VL        HIV          MON-1     17    A     5           2           
  P              Patient 19    MHOM/FR/2000/LPM 195    2000   VL        HIV          MON-1     18    A     2/5/3       1/3/2       
  AM             Patient 20    MHOM/FR/86/LPN30        1986   VL        HIV          MON-1     19    A/B                           
  AM             Patient 21    MHOM/FR/88/LPN50        1988   VL        HIV          MON-1     20    A     5           2           
  AM             Patient 29    MHOM/FR/84/LPN23        1984   VL                     MON-1     21    A     5           2           
  AM             Patient 30    MHOM/FR/85/LPN25a       1985   VL                     MON-1     21    A     5           2           
  AM             Patient 31    MHOM/FR/94/LPN112       1994   VL                     MON-1     21    A     5           2           
  P              Patient 22    MHOM/FR/96/LPM151       1996   VL        HIV          MON-1     21    A     5           2           
  AM             Patient 32    MHOM/FR/96/LPN132       1996   VL                     MON-1     21    A     5           2           
  P              Patient 23    MHOM/FR/97/LPM169       1997   VL        HIV          MON-1     21    A     5           2           
  P              Patient 24    MHOM/FR/97/LPM172       1997   VL        HIV          MON-1     21    A     5           2           
  P              Patient 35    MHOM/FR/2004/LPN228     2004   IVL                    MON-1     21    A     5           2           
  P              Patient 25    MHOM/FR/2005/LPM242     2005   IVL                    MON-1     21    A     5           2           
  P              Patient 26    MHOM/FR/2005/LPM247     2005   IVL                    MON-1     21    A     5           2           
  P              Patient 27    MHOM/FR/2009/LPM261     2009   IVL                    MON-1     21    A     5           2           
  AM                           MCAN/FR/95/LPN122\*            CanL                   MON-1     21    A     5           2           
  AM                           MCAN/FR/95/LPN123\*            CanL                   MON-1     21    A     5           2           
  AM                           MCAN/FR/95/LPN124\*            CanL                   MON-1     21    A     5           2           
  AM             Patient 33    MHOM/FR/96/LPN136\*     1996   AC                     MON-1     21    A     5           2           
  AM             Patient 34    MHOM/FR/96/LPN131\*     1996   AC                     MON-1     21    A     5           2           
  AM             Patient 28    MHOM/FR/81/LPN5         1981   IVL                    MON-1     21    A     5           2           
  AM             Patient 36    n\. d.                  2009   IVL                    MON-1     21    A     5           2           
  AM             Patient 37    MHOM/FR/90/LPN61        1990   IVL                    MON-1     22    A/B                           
  AM             Patient 38    MHOM/FR/2002/LPN199     2002   VL                     MON-1     23    A     3           1           
  P              Patient 39    MHOM/FR/2007/LPM255     2007   IVL                    MON-1     24    A     4/5/2       1           
  P              Patient 40    MHOM/FR/2002/LPM216     2002   VL        HIV          MON-1     25    A     4/3/2       1           
  P              Patient 41    MHOM/FR/2002/LPM217     2002   VL                     MON-1     25    A     4/3/2       1           
  P              Patient 42    MHOM/FR/98/LPM185       1998   VL        HIV          MON-1     26    A     4/5/6       1           
  CO             Patient 43    MHOM/FR/2006/LPM251     2006   IVL                    MON-24    27    A     2           1           
  AM             Patient 44    MHOM/FR/2001/LPN195     2001   VL                     MON-1     28    A     5/2/4       1/2         
  AM             Patient 45    MHOM/FR/2007/LPN312     2007   IVL                    MON-1     29    A     3           1           
  AM                           MCAN/FR/86/LPN28        1986   CanL                   MON-1     30    A     3           1           
  P              Patient 46    MHOM/FR/2003/LPN221     2003   CL                     MON-1     31    A     3/2         1           
  AM             Patient 47    MHOM/FR/97/LPN159       1997   VL                     MON-1     32    B/A                           
  AM             Patient 48    MHOM/FR/90/LPN64        1990   VL        HIV          MON-1     33    A     3           1           
  AM             Patient 49    MHOM/FR/89/LPN54        1989   VL                     MON-1     34    B                             1
  AM             Patient 50    MHOM/FR/91/LPN70        1991   IVL                    MON-1     34    B                             1
  AM             Patient 51    MHOM/FR/92/LPN78        1992   VL                     MON-1     34    B                             1
  AM             Patient 52    MHOM/FR/95/LPN116       1995   VL        HIV          MON-1     34    B                             1
  AM             Patient 53    MHOM/FR/96/LPN141       1996   VL                     MON-1     34    B                             1
  AM             Patient 54    MHOM/FR/97/LPN150       1997   IVL                    MON-1     34    B                             1
  AM             Patient 55    MHOM/FR/2001/LPN181     2001   IVL                    MON-1     34    B                             1
  AM             Patient 56    MHOM/FR/2007/LPN313     2007   CL                     MON-1     34    B                             1
  AM             Patient 57    MHOM/FR/2011/LPN358     2011   VL                     MON-1     34    B                             1
  AM                           MCAN/FR/89/LPN57        1989   CanL                   MON-1     35    A/B                           
  AM             Patient 58    MHOM/FR/95/LPN120       1995   VL        HIV          MON-1     35    A/B                           
  AM             Patient 60    MHOM/FR/92/LPN84        1992   IVL                    MON-1     36    A     3           1           
  AM             Patient 61    MHOM/FR/94/LPN103       1994   CL                     MON-1     36    A     3           1           
  AM             Patient 62    MHOM/FR/95/LPN115       1995   IVL                    MON-1     36    A     3           1           
  AM             Patient 63    MHOM/FR/95/LPN119       1995   VL        HIV          MON-1     36    A     3           1           
  CO             Patient 59    MHOM/FR/96/LPM157       1996   VL                     MON-1     36    A     3           1           
  AM             Patient 64    MHOM/FR/2001/LPN187     2001   VL                     MON-1     36    A     3           1           
  AM             Patient 64    MHOM/FR/2002/LPN198     2002   RVL                    MON-1     36    A     3           1           
  P              Patient 65    MHOM/FR/94/LPM112       1994   VL        HIV          MON-1     37    A     4/5/1       1/2/4       
  P              Patient 66    MHOM/FR/2006/LPM250     2006   VL                     MON-1     37    A     4/5/1       1/2/4       
  AM             Patient 67    MHOM/FR/93/LPN92        1993   VL        HIV          MON-1     38    A     2/1/3       3/4/1       
  P              Patient 68    MHOM/FR/97/LPM173       1997   VL                     MON-1     39    B                             1
  AM             Patient 69    MHOM/FR/86/LPN29        1986   VL        HIV          MON-1     40    A/B                           
  AM             Patient 71    MHOM/FR/87/LPN33        1987   IVL                    MON-1     41    A/B                           
  AM                           MCAN/FR/87/LPN34        1987   CanL                   MON-1     41    A/B                           
  AM             Patient 72    MHOM/FR/89/LPN51        1989   VL        HIV          MON-1     41    A/B                           
  AM             Patient 73    MHOM/FR/98/LPN164       1998   VL        HIV                    41    A/B                           
  AM             Patient 70    MHOM/FR/2005/LPM244     2005   VL        HIV          MON-1     41    A/B                           
  AM             Patient 74    MHOM/FR/96/LPN146       1996   VL        HIV          MON-1     42    B                             2
  AM             Patient 75    MHOM/TR/94/LPN101       1994   IVL                    MON-1     43    B                             1
  AM             Patient 76    MHOM/FR/94/LPN104       1994   IVL                    MON-1     43    B                             1
  AM             Patient 77    MHOM/FR/95/LPN113       1995   IVL                    MON-1     43    B                             1
  AM             Patient 78    MHOM/FR/95/LPN121       1995   VL        HIV          MON-1     43    B                             1
  AM             Patient 86    MHOM/FR/2002/LPN201     2002   RVL       HIV          MON-1     43    B                             1
  AM             Patient 87    MHOM/FR/2004/LPN233     2004   VL        HIV          MON-1     43    B                             1
  AM             Patient 79    MHOM/FR/96/LPN134\*     1996   AC                     MON-1     43    B                             1
  AM             Patient 80    MHOM/FR/96/LPN137\*     1996   AC                     MON-1     43    B                             1
  AM             Patient 81    MHOM/FR/96/LPN138\*     1996   AC                     MON-1     43    B                             1
  AM             Patient 82    MHOM/FR/96/LPN144\*     1996   AC                     MON-1     43    B                             1
  AM             Patient 83    MHOM/FR/96/LPN143\*     1996   AC                     MON-1     43    B                             1
  AM             Patient 84    MHOM/FR/96/LPN142\*     1996   AC                     MON-1     43    B                             1
  AM             Patient 85    MHOM/IT/96/LPN145\*     1996   AC                     MON-1     43    B                             1
  AM             Patient 88    MHOM/FR/80/LPN3         1980   IVL                    MON-1     44    B                             1
  AM             Patient 89    MHOM/00/94/LPN108       1994   VL        HIV          MON-1     44    B                             1
  AM             Patient 90    MHOM/FR/2004/LPN236     2004   VL                     MON-1     45    B                             1
  AM                           MCAN/FR/82/LPN16        1983   CanL                   MON-1     46    B                             1
  AM             Patient 91    MHOM/FR/83/LPN19        1983   VL                     MON-1     46    B                             1
  AM             Patient 92    MHOM/FR/84/LPN20        1984   VL                     MON-1     46    B                             1
  AM             Patient 93    MHOM/FR/85/LPN24        1985   VL                     MON-1     46    B                             1
  AM                           MCAN/FR/87/LPN37        1987   CanL                   MON-1     46    B                             1
  AM             Patient 94    MHOM/FR/88/LPN46        1988   VL                     MON-1     46    B                             1
  AM             Patient 95    MHOM/FR/89/LPN59        1989   VL        HIV          MON-1     46    B                             1
  AM             Patient 96    MHOM/FR/93/LPN91        1993   IVL                    MON-1     46    B                             1
  AM             Patient 97    MHOM/00/93/LPN94        1993   VL        HIV          MON-1     46    B                             1
  AM             Patient 98    MHOM/FR/95/LPN107       1994   IVL                    MON-1     46    B                             1
  AM             Patient 99    MHOM/FR/95/LPN114       1994   IVL                    MON-1     46    B                             1
  AM             Patient 100   MHOM/FR/95/LPN118       1995   VL        HIV          MON-1     46    B                             1
  AM             Patient 101   MHOM/FR/96/LPN125       1996   VL                     MON-1     46    B                             1
  AM             Patient 102   MHOM/FR/97/LPN148       1997   VL        HIV          MON-1     46    B                             1
  P              Patient 105   MHOM/FR/97/LPM139       1995   VL        HIV          MON-1     46    B                             1
  AM             Patient 103   MHOM/FR/97/LPN152       1997   VL                     MON-1     46    B                             1
  AM             Patient 104   MHOM/FR/2001/LPN180     2001   IVL                    MON-1     46    B                             1
  AM             Patient 106   MHOM/FR/2005/LPN257     2005   IVL                    MON-1     47    B                             1
  AM             Patient 107   MHOM/FR/84/LPN21        1984   VL                     MON-1     48    B                             1
  AM             Patient 108   MHOM/FR/92/LPN85        1992   IVL                    MON-1     48    B                             1
  AM             Patient 109   MHOM/FR/2004/LPN240     2004   VL                     MON-1     48    B                             1
  AM             Patient 110   n\. d.                  2011   IVL                    MON-1     49    B                             1
  AM             Patient 111   MHOM/FR/92/LPN86        1992   IVL                    MON-1     50    B                             2
  AM             Patient 112   MHOM/FR/2001/LPN191     2001   VL        HIV          MON-1     50    B                             2
  AM             Patient 113   MHOM/FR/2008/LPN321     2008   VL                     MON-1     50    B                             2
  AM             Patient 114   MHOM/FR/99/LPN170       1999   VL                     MON-1     51    B                             2
  AM             Patient 115   MHOM/FR/2006/LPN281     2006   VL                     MON-1     52    B                             2
  CE                           MCAN/FR/2006/LPN285     2006   CanL                   MON-1     52    B                             2
  AM             Patient 116   MHOM/FR/87/LPN36        1987   VL        HIV          MON-1     53    B                             2
  AM             Patient 117   MHOM/FR/91/LPN71        1991   VL        HIV          MON-1     53    B                             2
  AM             Patient 118   MHOM/FR/93/LPN96        1992   VL                     MON-1     53    B                             2
  AM             Patient 119   MHOM/FR/93/LPN99        1993   VL        HIV          MON-1     53    B                             2
  AM                           MCAN/FR/94/LPN102       1994   CanL                   MON-1     53    B                             2
  AM             Patient 120   MHOM/FR/95/LPN117       1995   VL                     MON-1     53    B                             2
  AM             Patient 121   MHOM/FR/2001/LPN189     2001   VL                     MON-1     53    B                             2
  AM             Patient 122   MHOM/FR/78/LPN1         1978   VL                     MON-1     54    B                             2
  AM                           MCAN/FR/82/LPN6         1982   CanL                   MON-1     55    B                             2
  AM             Patient 123   MHOM/FR/84/LPN22        1983   VL                     MON-1     55    B                             2
  AM             Patient 124   MHOM/FR/86/LPN31        1986   VL                     MON-1     55    B                             2
  AM             Patient 125   MHOM/FR/88/LPN48        1988   CL                     MON-1     55    B                             2
  AM             Patient 126   MHOM/FR/89/LPN55        1989   IVL                    MON-1     55    B                             2
  AM             Patient 127   MHOM/FR/90/LPN68        1990   IVL                    MON-1     55    B                             2
  AM             Patient 128   MHOM/FR/92/LPN76        1992   VL                     MON-1     55    B                             2
  AM             Patient 129   MHOM/FR/92/LPN77        1992   VL        HIV          MON-1     55    B                             2
  AM             Patient 130   MHOM/FR/92/LPN80        1992   VL        HIV          MON-1     55    B                             2
  AM             Patient 131   MHOM/FR/92/LPN82        1992   VL        HIV          MON-1     55    B                             2
  CO             Patient 146   MHOM/FR/93/LPN95        1993   VL                     MON-1     55    B                             2
  AM             Patient 132   MHOM/FR/94/LPN106       1994   VL                     MON-1     55    B                             2
  AM             Patient 133   MHOM/FR/94/LPN109       1994   VL        HIV          MON-1     55    B                             2
  AM             Patient 135   MHOM/FR/96/LPN133       1996   IVL                    MON-1     55    B                             2
  AM             Patient 134   MHOM/FR/96/LPN130       1996   VL                     MON-1     55    B                             2
  AM                           MFEL/FR/96/LPN139       1996   CatL                   MON-1     55    B                             2
  AM             Patient 136   MHOM/FR/97/LPN155       1997   VL                     MON-1     55    B                             2
  AM             Patient 137   MHOM/FR/97/LPN158       1997   VL                     MON-1     55    B                             2
  AM             Patient 139   MHOM/FR/2000/LPN176     2000   VL                     MON-1     55    B                             2
  AM             Patient 138   MHOM/FR/2000/LPN175     2000   VL                     MON-1     55    B                             2
  AM             Patient 140   MHOM/FR/2003/LPN209     2003   IVL                    MON-1     55    B                             2
  AM             Patient 141   MHOM/FR/2003/LPN217     2003   VL                     MON-1     55    B                             2
  AM             Patient 142   MHOM/FR/2006/LPN259     2006   VL                     MON-1     55    B                             2
  AM             Patient 143   MHOM/FR/2006/LPN282     2006   IVL                    MON-1     55    B                             2
  AM             Patient 144   MHOM/FR/2007/LPN316     2007   VL                     MON-1     55    B                             2
  AM             Patient 145   MHOM/FR/2011/LPN357     2011   VL                     MON-1     55    B                             2
  AM             Patient 147   MHOM/FR/96/LPN127       1996   VL        HIV          MON-1     56    B                             2
  AM                           MCAN/FR/82/LPN10        1982   CanL                   MON-1     57    B                             2
  AM             Patient 148   MHOM/FR/89/LPN53        1989   VL                     MON-1     57    B                             2
  AM             Patient 149   MHOM/FR/90/LPN66        1990   VL                     MON-1     57    B                             2
  AM             Patient 150   MHOM/FR/93/LPN90        1993   VL                     MON-1     57    B                             2
  AM             Patient 151   MHOM/FR/93/LPN93        1993   IVL                    MON-1     57    B                             2
  AM             Patient 152   MHOM/FR/93/LPN98        1993   VL        HIV          MON-1     57    B                             2
  AM             Patient 153   MHOM/FR/94/LPN110       1994   VL        HIV          MON-1     57    B                             2
  AM             Patient 154   MHOM/FR/96/LPN140       1996   IVL                    MON-1     57    B                             2
  AM             Patient 155   MHOM/FR/97/LPN156       1997   VL        HIV          MON-1     57    B                             2
  AM             Patient 156   MHOM/FR/2000/LPN178     2000   IVL                    MON-1     57    B                             2
  AM             Patient 157   MHOM/FR/2001/LPN190     2001   IVL                    MON-1     57    B                             2
  AM             Patient 158   MHOM/FR/2006/LPN277     2006   VL                     MON-1     57    B                             2
  AM             Patient 159   MHOM/FR/2011/LPN351     2011   IVL                    MON-1     57    B                             2
  AM             Patient 160   MHOM/FR/2011/LPN356     2011   IVL                    MON-1     57    B                             2
  AM             Patient 161   MHOM/FR/2011/LPN366     2011   IVL                    MON-1     57    B                             2
  AM             Patient 162   MHOM/FR/2004/LPN237     2004   VL                     MON-1     58    B                             2
  CO             Patient 163   MHOM/FR/94/LPN105       1994   VL        HIV          MON-1     59    B                             1
  P              Patient 164   MHOM/FR/96/LPM154       1996   IVL                    MON-1     60    A     3/4/5/2     1           
  P              Patient 165   MHOM/FR/97/LPM174       1997   VL        HIV          MON-1     61    A     4/3/2       1           
  AM             Patient 166   MHOM/FR/99/LPN173       1999   IVL                    MON-1     62    A/B                           
  P              Patient 167   MHOM/FR/97/LPM170       1997   IVL                    MON-1     63    A     1           4           
  P              Patient 168   MHOM/FR/97/LPM177       1997   VL        HIV          MON-1     63    A     1           4           
  P              Patient 169   MHOM/FR/2000/LPM201     2000   VL        HIV          MON-1     63    A     1           4           
  P              Patient 170   MHOM/FR/2001/LPM209     2001   VL        HIV          MON-1     64    A     1/3/4/2     4/1/2       
  P              Patient 171   MHOM/FR/97/LPM166       1997   VL        HIV          MON-1     65    A     1           4           
  P              Patient 172   MHOM/FR/2004/LPM236     2004   IVL                    MON-1     66    A     1           4           
  P              Patient 173   MHOM/FR/2006/LPM252     2006   VL                     MON-1     67    A     1           4           
  P              Patient 174   MHOM/FR/94/LPM116       1994   VL        HIV          MON-1     68    A     1           4           
  P              Patient 175   MHOM/FR/96/LPM138       1996   VL        HIV          MON-1     68    A     1           4           
  P              Patient 176   MHOM/FR/99/LPM189       1999   IVL                    MON-1     68    A     1           4           
  P              Patient 177   MHOM/FR/2000/LPM204     2000   IVL                    MON-1     68    A     1           4           
  P              Patient 178   MHOM/FR/98/LPM183       1998   VL        HIV          MON-1     69    A     1/3/2       4           
  P              Patient 179   MHOM/FR/97/LPM178       1997   UK                     MON-1     69    A     1/3/2       4           
  P              Patient 180   MHOM/FR/2003/LPM232     2003   IVL                    MON-1     70    A     1           4           
  P              Patient 181   MHOM/FR/96/LPM152       1996   VL                     MON-1     71    A     1/3/2       4           
  P              Patient 182   MHOM/FR/97/LPM168       1997   VL        HIV          MON-1     72    A     1           4           
  P              Patient 183   MHOM/FR/98/LPM181       1998   MCL                    MON-1     73    A     5           2           
  P              Patient 184   MHOM/FR/96/LPM156       1996   IVL                    MON-1     74    A     5/1/4/2     2/4/1       
  CE                           IPER/FR/84/LEM576\*     1984   PHLE                   MON-1     75    A     4/1/2       1/4         
  CE                           IARI/FR/84/LEM595\*     1984   PHLE                   MON-1     75    A     4/1/2       1/4         
  AM             Patient 185   MHOM/FR/96/LPN129       1996   VL        HIV          MON-1     76    A     1           4           
  AM             Patient 186   MHOM/FR/88/LPN45        1988   VL        HIV          MON-1     77    A     1           4           
  AM             Patient 187   MHOM/FR/89/LPN58        1989   IVL                    MON-1     77    A     1           4           
  AM             Patient 188   MHOM/FR/91/LPN69        1991   VL        HIV          MON-1     77    A     1           4           
  AM             Patient 189   MHOM/FR/96/LPN128       1996   VL        HIV          MON-1     77    A     1           4           
  AM             Patient 190   MHOM/FR/97/LPN151       1996   VL        HIV          MON-1     77    A     1           4           
  AM             Patient 86    MHOM/FR/97/LPN153       1997   VL        HIV          MON-1     77    A     1           4           
  AM                           MCAN/FR/98/LPN168       1998   CanL                             77    A     1           4           
  AM             Patient 86    MHOM/FR/2000/LPN177     2000   RVL       HIV          MON-1     77    A     1           4           
  AM             Patient 86    MHOM/FR/2001/LPN185     2001   RVL       HIV          MON-1     77    A     1           4           
  AM             Patient 191   MHOM/FR/2001/LPN186     2001   VL        HIV          MON-1     77    A     1           4           
  AM             Patient 86    MHOM/FR/2003/LPN215     2003   RVL       HIV          MON-1     77    A     1           4           
  AM             Patient 192   MHOM/FR/2007/LPN314\*   2007   VL        HIV          MON-1     78    A     1/6         4/3/1       
  AM                           MCAN/FR/2006/LPN267     2006   CanL                   MON-1     79    A     1/6/3/4     4/2/3       
  P              Patient 193   MHOM/FR/2002/LPM222     2002   VL        HIV          MON-1     80    A     1/5/6       4/2         
  P              Patient 194   MHOM/FR/2001/LPM214     2001   VL                     MON-1     81    A     2/4         1           
  P              Patient 195   MHOM/FR/2002/LPM226     2002   VL        HIV          MON-1     82    A     2/4         1           
  P              Patient 196   MHOM/FR/2002/LPM228     2002   VL                     MON-1     83    A     2/4         1           
  P              Patient 197   MHOM/FR/96/LPM155       1996   VL                     MON-1     84    A     2/3/1       1           
  P              Patient 198   MHOM/FR/96/LPM159       1996   VL                     MON-1     84    A     2/3/1       1           
  P              Patient 199   MHOM/FR/94/LPM133       1994   VL        HIV          MON-1     85    A     2           1           
  P              Patient 200   MHOM/FR/96/LPM161       1996   IVL       HIV          MON-1     85    A     2           1           
  P              Patient 201   MHOM/FR/2009/LPM264     2009   MCL                    MON-1     85    A     2           1           
  P              Patient 202   MHOM/FR/94/LPM122-2     1994   VL        HIV          MON-1     86    A     1/3/4       4/1         
  P              Patient 203   MHOM/FR/2001/LPM212     2001   CL                     MON-1     87    A     4/3/2       1           
  P              Patient 204   MHOM/FR/2008/LPM260     2008   VL        HIV          MON-1     88    A     2           1/3         
  P              Patient 205   MHOM/FR/99/LPM191       1999   CL        HIV          MON-1     89    A     1/3         1/4         
  P              Patient 206   MHOM/FR/95/LPM137       1995   VL        HIV          MON-1     90    A     3/6         1/3         
  P              Patient 207   MHOM/FR/2000/LPM196     2000   VL        HIV          MON-1     91    A     4           1           
  P              Patient 208   MHOM/FR/94/LPM118       1994   VL        HIV          MON-108   92    A     4/1/5       1/2/4       
  CE             Patient 212   MHOM/FR/85/LEM716\*     1985   VL                     MON-1     93    A     4           1           
  P              Patient 210   MHOM/FR/97/LPM176       1997   IVL                    MON-1     93    A     4           1           
  CO             Patient 209   MHOM/FR/98/LPM186       1998   VL                     MON-1     93    A     4           1           
  P              Patient 211   MHOM/FR/2001/LPN183     2001   VL                     MON-1     93    A     4           1           
  AM             Patient 213   MHOM/FR/83/LPN18        1983   VL                     MON-1     94    A     4           1           
  CE             Patient 214   MHOM/FR/87/LEM1098\*    1987   CL                     MON-1     94    A     4           1           
  CE             Patient 215   MHOM/FR/78/LEM75\*      1978   VL                     MON-1     94    A     4           1           
  CE             Patient 216   MHOM/FR/85/LEM663\*     1985   VL                     MON-1     95    A     4           1           
  AM             Patient 217   MHOM/FR/88/LPN41        1988   VL        HIV          MON-1     96    A     2/5         3/2         
  AM             Patient 218   MHOM/FR/2003/LPN213     2003   VL                     MON-1     97    A     4           1           
  AM             Patient 219   MHOM/FR/96/LPM162       1996   CL                     MON-24    98    A     6           3           
  AM             Patient 220   MHOM/00/2004/LPN234     2004   CL                     MON-24    99    A     6           3           
  AM             Patient 190   MHOM/FR/2001/LPN182     2001   RVL       HIV          MON-1     100   A     1           4           
  AM             Patient 190   MHOM/FR/2001/LPN188     2001   RVL       HIV          MON-1     100   A     1           4           
  P              Patient 221   MHOM/FR/2000/LPM200     2000   VL        HIV          MON-1     101   A     2/1         1/3/4       
  P              Patient 222   MHOM/FR/94/LPM120       1994   VL        HIV          MON-1     102   A     2/1/3       1/4         
  P              Patient 223   MHOM/FR/99/LPM194       1999   MCL                    MON-1     103   A     4/3/2       1           
  P              Patient 224   MHOM/FR/96/LPM158       1996   VL                     MON-1     104   A     4/2/5       1/2         
  AM                           MCAN/FR/80/LPN4         1980   CanL                   MON-1     105   A     4/3/2       1           
  AM                           MCAN/FR/82/LPN8         1982   CanL                   MON-1     105   A     4/3/2       1           
  AM             Patient 225   MHOM/FR/99/LPN171       1999   IVL                    MON-1     106   A     3           1           
  P              Patient 226   MHOM/FR/2001/LPM211     2001   VL        HIV          MON-1     107   A     3           1           
  P              Patient 227   MHOM/00/00/LPM148       1995   UK                     MON-1     108   A     3           1           
  AM             Patient 228   n\. d.                  2011   VL                     MON-1     109   A     3           1           
  AM                           MCAN/FR/86/LPN27        1986   CanL                   MON-1     110   A     3           1           
  AM             Patient 229   MHOM/FR/99/LPN174       1999   CL                     MON-24    111   A     6           3           
  AM             Patient 230   MHOM/FR/2005/LPN253     2001   VL        HIV          MON-80    112   A     6           3           
  P              Patient 231   MHOM/00/2003/LPM233     2003   IVL                    MON-1     113   A     2           3           
  CO             Patient 232   MHOM/FR/2000/LPM205     2000   VL                     MON-1     114   A     6           3           
  CO             Patient 233   MHOM/FR/92/LPN83        1991   CL        HIV          MON-1     115   A     6           3           
  CO             Patient 234   MHOM/FR/99/LPM190       1999   VL        HIV          MON-1     116   A     6           3           
  AM             Patient 235   MHOM/FR/89/LPN60        1989   VL        HIV          MON-1     117   A     2           1/3         
  P              Patient 236   MHOM/FR/2008/LPM259     2008   VL        HIV          MON-1     118   A     2/1         1/4/3       
  P              Patient 237   MHOM/FR/2007/LPM254     2007   IVL                    MON-1     119   A     6           3           
  AM             Patient 238   MHOM/FR/93/LPN97        1993   CL                     MON-24    120   A     6           3           
  P              Patient 239   MHOM/FR/95/LPM136       1995   VL        HIV          MON-1     121   A     6           3           

Legend of columns: Endemic area: AM: Alpes-Maritimes; P: Provence; CE: Cévennes; CO: Corsica. Patients: Anonymized name given to the patients. Sample WHO code: WHO code of the isolates; The MLMT profile of the samples indicated with \* was already characterized by Hide et al \[[@pntd.0004303.ref009]\]; n. d. = not defined. Y: Year of isolation. C F / H: Clinical form of the disease and/or host: VL--visceral leishmaniasis; IVL--Infant under 15 years with visceral leishmaniasis; CL--cutaneous leishmaniasis; MCL--muco-cutaneous leishmaniasis; RVL---New episode of leishmaniasis in VL patient; AC--asymptomatic carrier; CanL--canine leishmaniasis; CatL--leishmaniasis in cat; PHLE--sample isolated from phlebotomine sandfly; UK--unknown. Zymo: zymodeme of isolate. G: genotypes. P: population as defined by STRUCTURE.

Concerning the geographical distribution ([Fig 1](#pntd.0004303.g001){ref-type="fig"}), the samples were collected from the endemic areas of AM (n = 178), P (n = 75), CO (n = 9) and CE (n = 8). The samples were isolated at the University Hospitals of Nice, Marseille and Montpellier (France) between 1978 and 2011. MLEE typing and cryoconservation were performed at the Centre National de Référence des *Leishmania* (*Leishmania* collection, BRC-Leish, Montpellier, France, BioBank N° BB-0033-00052). Overall, 259 isolates were characterized as zymodeme MON-1, six were MON-24, one was MON-11, one was MON-80 and one was MON-108. The data were unavailable for two isolates. For this study, the primary cultures from the patient stored at -80°C were thawed and the cells were cultured for six days before harvesting for DNA extraction.

![Geographical distribution of isolates from Southeastern France.\
Isolates clustered into four endemic areas. The geographic areas where samples were isolated from Cévennes (blue), Provence (green), Alpes-Maritimes (red) and Corsica (violet) are indicated. The Alpes-Maritimes and Provence endemic areas are located in the PACA region.](pntd.0004303.g001){#pntd.0004303.g001}

DNA extraction {#sec004}
--------------

The microsatellite data indicated with an asterisk in [Table 1](#pntd.0004303.t001){ref-type="table"} were obtained from a previous study \[[@pntd.0004303.ref009]\].

DNA of the remaining isolates was extracted from promastigotes grown in Schneider's insect medium (Sigma Aldrich, France) supplemented with serum calf, urine, penicillin, streptomycin and L-glutamine (Sigma Aldrich). Promastigotes were harvested on the sixth day of culture, and DNA was extracted from a pellet of 2X10^8^ parasites using a QIAamp DNA mini kit (Qiagen, France) according to the manufacturer's instructions. DNA extracted from the strain MHOM/FR/85/LEM716 was used as a control to determine the size of amplified microsatellite fragments, as this microsatellite data have been published \[[@pntd.0004303.ref009]\].

Multi-Locus Microsatellite Typing (MLMT) {#sec005}
----------------------------------------

Twelve microsatellite loci were amplified using the PCR conditions as previously described: LiBTG, LiBTA, LIST7021, LIST7025, LIST7026, LIST7031, LIST7033, Li22-25, Li45-24, TubCA, Li71-5/2 and Rossi2 \[[@pntd.0004303.ref009]--[@pntd.0004303.ref012]\]. The amplification products were analyzed using an automated capillary ABI Prism 3130XL Genetic Analyzer (Applied Biosystems, France). The data were stored and analyzed using GeneMapper analysis software (version 4.0, Applied Biosystems). PCR fragment sizes were determined using the internal size standard GeneScan 500 LIZ (Applied Biosystems). All 270 *Leishmania* isolates were genotyped at each of the 12 loci. With the PCR fragment size of the control strain MHOM/FR/85/LEM716, we were able to include microsatellite data from the Hide et al. study (data indicated with an asterisk in [Table 1](#pntd.0004303.t001){ref-type="table"}). Four isolates from this previous study (MCAN/FR/95/LPN122, MCAN/FR/95/LPN123, MCAN/FR/95/LPN124, and MCAN/FR/95/LPN124) were re-extracted from culture and re-genotyped blindly. The same microsatellite results described by Hide et al. were obtained \[[@pntd.0004303.ref008]\].

Genetic diversity and differentiation analysis {#sec006}
----------------------------------------------

Descriptive statistics for the observed genetic populations were calculated using Genetix version 4.05.2 (2004) and FSTAT Version 2.9.3.2 \[[@pntd.0004303.ref013]\]. Using these programs, we calculated allelic diversity (number of allelic variants per maker), expected (*He*) and observed (*Ho*) heterozygosity, genetic diversity within subsamples *Hs*, inbreeding coefficient (*F*~IS~) the migration rates (gene flow) (*Nm*) \[[@pntd.0004303.ref014]\]. The *Fst* value, which indicates the degree of genetic differentiation and gene flow among populations was also calculated. *Fst* values above 0.25 with significant *p*- values (\<0.05) indicated strong genetic differentiation \[[@pntd.0004303.ref015]\].

Clustering and phenetic analyses {#sec007}
--------------------------------

Phylogenetic analyses were performed based on the microsatellite profiles. A distance matrix was calculated using the Chord distance (Cavalli-Sforza and Edwards 1967) setting in the POPULATIONS 1.2.31 software with bootstrap values determined for 1,000 replicates (<http://bioinformatics.org/~tryphon/populations/>) \[[@pntd.0004303.ref016]\]. The resulting distance matrix was processed using MEGA 4.0.2 to construct an unrooted Neighbor-Joining (NJ) tree \[[@pntd.0004303.ref017]\].

The genetic characteristics of the *Leishmania* samples were also investigated using a model-based Bayesian clustering method implemented in STRUCTURE v 2.3.4 \[[@pntd.0004303.ref018]\]. This algorithm simultaneously estimates the allele frequencies to assign individuals into genetically distinct populations (*K*) and each probability for the identification of the most likely number of populations. A series of ten independent runs was performed for each K value between one and ten. The following parameters were used: burn in period of 20,000 iterations, 200,000 Markov Chain Monte Carlo iterations and admixture model. The most probable number of clusters was identified via calculation of the Delta *K* (*ΔK*), which is based on the rate of change in the log probability of data between successive K values. The peak of the *ΔK* graph corresponds to the most probable number of populations in the data set \[[@pntd.0004303.ref019]\].

Statistical analysis {#sec008}
--------------------

A chi-square statistical test was performed to determine whether the observed data differed significantly from the expected ratios. The chi-square value was considered significant when p≤0.05. This test was used to compare the proportion of HIV+ patients in Populations A and B.

Results {#sec009}
=======

Microsatellite analysis {#sec010}
-----------------------

In total, 270 isolates were typed at 12 microsatellite markers with one or two alleles at each locus. All markers were polymorphic. The number of alleles per locus (*N*a) ranged from 3 to 13. Li22-35, LIST7021, LiBTG, LiBTA and LIST7026 were the most polymorphic markers with 13, 12, 10, 9 and 8 alleles, respectively. LIST7031, Li71-5/2 and LIST7025 were the least polymorphic markers with three different alleles ([Table 2](#pntd.0004303.t002){ref-type="table"}).

10.1371/journal.pntd.0004303.t002

###### Descriptive statistics of the 270 isolates analyzed at the 12 microsatellite markers.

![](pntd.0004303.t002){#pntd.0004303.t002g}

  Locus      Na     *He*    *Ho*    *Hs*    *F*~IS~
  ---------- ------ ------- ------- ------- ---------
  Li22-35    13     0.644   0.082   0.645   0.874
  LIST7021   12     0.547   0.037   0.548   0.933
  LiBTG      10     0.620   0.041   0.621   0.935
  LiBTA      9      0.809   0.174   0.811   0.786
  LIST7026   8      0.690   0.033   0.691   0.952
  TubCA      7      0.541   0.041   0.542   0.925
  Li45-24    6      0.649   0.026   0.650   0.960
  Rossi2     6      0.553   0.019   0.554   0.967
  LIST7033   6      0.533   0.019   0.534   0.965
  LIST7031   3      0.230   0.026   0.231   0.888
  LIST7025   3      0.240   0.019   0.224   0.918
  Li71-5/2   3      0.502   0.011   0.503   0.978
  Overall    7.17   0.545   0.044   0.546   0.920

*Na*: number of alleles per locus; *He*: expected heterozygosity; *Ho*: observed heterozygosity; *Hs*: genetic diversity; *F*~IS~: inbreeding coefficient.

Genetic variability was analyzed among the 12 microsatellite loci ([Table 2](#pntd.0004303.t002){ref-type="table"}). The *Ho* was weak and ranged from 0.011 to 0.174 for Li71-5/2 and LiBTA, respectively, with an overall *Ho* at 0.044. The mean intra-population *Hs* was 0.546 (0.224--0.811) for the entire sample set and 0.531 (0.208--0.804) for the MON-1 population ([Table 2](#pntd.0004303.t002){ref-type="table"}). The *F*~IS~ for the entire population was 0.920, thereby indicating a considerable degree of inbreeding. A separate analysis was performed to investigate the genetic polymorphisms among the four geographically determined populations ([Table 3](#pntd.0004303.t003){ref-type="table"}). Extensive inbreeding in the four populations was observed, with the highest inbreeding coefficient found in the populations of the CO and AM endemic areas. The genetic differentiation among the four endemic areas was tested using FSTAT version 2.9.3.2 ([Table 4](#pntd.0004303.t004){ref-type="table"}). The *F*st values ranged from 0.067 to 0.321. All *F*st values between the four endemic areas were significant. We obtained lower values for P versus CE and P versus CO and higher values for AM versus CE and CO versus CE (which may be due to the low number of isolates collected from CE and CO). When comparing AM and P samples from 1993 to 2009 (corresponding to the time period of the isolation of samples from the P endemic area used in this study), the *F*st value obtained was similar to the *F*st value corresponding to the complete period of sample collection (1978 to 2011).

10.1371/journal.pntd.0004303.t003

###### Genetic diversity among the four endemic areas based on the MLMT profiles of the 12 analyzed markers.

![](pntd.0004303.t003){#pntd.0004303.t003g}

       Na      *He*    *Ho*    *F*~IS~
  ---- ------- ------- ------- ---------
  AM   6.333   0.462   0.030   0.936
  P    5.417   0.498   0.079   0.844
  CO   3.000   0.568   0.028   0.956
  CE   2.250   0.281   0.042   0.869

*Na*: Number of alleles per locus, *He*: expected heterozygosity, *Ho*: observed heterozygosity, *F*~IS~: inbreeding coefficient.

AM = Alpes-Maritimes, P = Provence, CO = Corsica and CE = Cévennes.

10.1371/journal.pntd.0004303.t004

###### Genetic differentiation between the isolates from the four endemic areas analyzed using *F*-statistics with the corresponding *p*-values.

![](pntd.0004303.t004){#pntd.0004303.t004g}

  Endemic areas                                                                          Number of isolates   *F*st       p-value
  -------------------------------------------------------------------------------------- -------------------- ----------- -----------
  **P vs. AM**                                                                           **75 / 178**         **0.239**   **0.008**
  **P vs. CO**                                                                           **75 / 9**           **0.126**   **0.008**
  **P vs. CE**                                                                           **75 / 8**           **0.067**   **0.050**
  **CO vs. CE**                                                                          **9 / 8**            **0.270**   **0.008**
  **AM vs. CO**                                                                          **178 / 9**          **0.161**   **0.008**
  **AM vs. CE**                                                                          178 / 8              **0.321**   **0.008**
  **P vs. AM isolates collected during same period of time (1993 to 2009)**              **75 / 111**         **0.236**   **0.050**
  **Sub-population defined according to their position in relation to the Vars river**                                    
  **AM East Vars vs. AM West Vars**                                                      **122 / 50**         **0.062**   **0.050**
  **AM West Vars vs. P**                                                                 **52 / 75**          **0.144**   **0.050**
  **P vs. AM East Vars**                                                                 **75 / 122**         **0.308**   **0.050**
  **Sub-population within the P endemic area**                                                                            
  Within P: Marseille vs. Toulon                                                         42 / 7               0.033       0.850
  Within P: Marseille vs. Other cities In P                                              42 / 33              0.012       0.550

Sub-populations were also defined according to their position in relation to Vars River ([S1 Table](#pntd.0004303.s001){ref-type="supplementary-material"}). This river is located in the southeast of France and flows in the Alpes-Maritimes Department. The *F*st values highlighted a gradient of differentiation from the East Vars to the West Vars and up to the P endemic area. A high and significant genetic differentiation (*F*st = 0.308) was obtained when comparing isolates from east of the Vars River and the P endemic area. The comparison of sub-populations isolated from the P endemic area failed to show any genetic differentiation (Marseille versus Toulon or Marseille versus other cities in the P endemic area), with the limitation that few samples were collected from Toulon (n = 7).

Geographical distribution of isolates from the two main endemic areas of AM and P {#sec011}
---------------------------------------------------------------------------------

A total of 121 different genotypes were identified from the 270 isolates corresponding to a genotype frequency of 0.037. The entire sample set comprised 91 unique genotypes (75%). Among the 30 repeated genotypes, seven were common to two endemic areas, one was common to three endemic areas and 22 pertained to the same focus ([Fig 2](#pntd.0004303.g002){ref-type="fig"}). The genotypes 21 (primarily) and 46 were found in both endemic areas of AM and P ([Fig 2](#pntd.0004303.g002){ref-type="fig"}). Within these endemic areas, Faucher et al. have described high- and low-risk sub-areas of VL \[[@pntd.0004303.ref005]\]. In our study, the repeated genotypes were almost exclusively found in high-risk areas, with the only exception of genotype 21 which was found in high and low risk sub-areas ([Fig 3A and 3B](#pntd.0004303.g003){ref-type="fig"}). Among the 30 repeated genotypes, 11 were found in four or more samples. These 11 genotypes represented 132 isolates.

![Repeated genotypes.\
Arbitrary numbers assigned to the 30 repeated genotypes in (x-axis) and number of isolates belonging to each genotype (y-axis). The origin of each isolates is indicated by the different colors.](pntd.0004303.g002){#pntd.0004303.g002}

![A. Localization of the genotypes.\
Eleven repeated genotypes, which were observed in four or more isolates, are represented with colored squares on the map of the endemic areas of Alpes-Maritimes and Provence. The two endemic areas are separated by a blue line. The remaining genotypes are represented by light brown squares. The area in the black rectangle is shown in further detail in Fig 3B. B. Detailed localization of isolates in the Alpes-Maritimes endemic area and more precisely the surrounding region of Nice. Isolates were localized at the city level. The black line represents the delimitation of Nice.](pntd.0004303.g003){#pntd.0004303.g003}

Temporal analysis of genotypes {#sec012}
------------------------------

The isolates were collected over the course of a 33-year period from 1978 to 2011 ([Fig 4](#pntd.0004303.g004){ref-type="fig"}). The repeated genotypes, found in four or more samples, were isolated over a period of six (genotype 68) to 29 years (genotypes 57 and 55). All genotypes except 68, 36, 34 and 43 were isolated from both humans and dogs. Genotype 21 was found to be present in the AM and P endemic areas over the course of 28 years. This genotype was first isolated in 1981 in the AM endemic area and then in 1996, at which time it was first identified in both the AM and P endemic areas. After 1996, genotype 21 was only isolated in the P. Finally, in 2009, this genotype was found in both the AM and P endemic areas. Genotype 21 was isolated from a variety of patients including asymptomatic carriers (AC), adult VL, infant VL and HIV+ VL cases.

![Temporal distribution of the 11 genotypes represented by more than four isolates.](pntd.0004303.g004){#pntd.0004303.g004}

Relapse and re-infection {#sec013}
------------------------

Four patients (patients 4, 64, 86 and 190) experienced more than one episode of VL ([Table 1](#pntd.0004303.t001){ref-type="table"}). Three of these patients were HIV+ (patients 4, 86 and 190). The isolates derived from patient 4 and 64 (HIV+ and HIV-, respectively), which were collected during a first VL episode (2003 for patient 4 and 2001 for patient 64) and second VL episode (one year later), presented identical MLMT profiles. In both cases, relapse was suspected. Patient 190 (HIV+) presented three episodes of VL, for which the second and third (2001 for both episodes) isolates differed from the first isolate (1996) at only one marker (LIST7021). Re-infection was suspected for this patient; however, further studies are warranted to confirm whether only one allelic change can lead to the suspicion of a re-infection or reflects the evolution of the isolate over time. Patient 86 (HIV+) presented five different episodes of VL due to active chronic VL \[[@pntd.0004303.ref020]\]. Isolates from the second (2000), third (2001) and last episode (2003) presented with the same MLMT profile compared with the isolate from the initial infection (1997). However, the MLMT profile of the fourth episode (2002) isolate varied at 11 loci; only Rossi2 remained the same. Re-infection and relapse were suspected for this patient. Each isolate of these multiple episodes was characterized zymodeme MON-1.

Association between genotype and clinical manifestation {#sec014}
-------------------------------------------------------

Genetic differentiation among the various populations was tested using FSTAT Version 2.9.3.2.

In France, at the end of the 1990s and early 2000s, the repellent collar had been widely use to protect dogs from parasitic transmission \[[@pntd.0004303.ref021],[@pntd.0004303.ref022]\]. To determine whether this had an impact on genetic differentiation, we compared the isolates before and after the introduction of repellent collar in the AM and P endemic areas. To minimize the temporal effect on genetic variability and determine whether the repellent collar led to a bottleneck effect, the samples collected between 1996 and 2004 were excluded ([Table 5](#pntd.0004303.t005){ref-type="table"}). No differentiation was found in both endemic areas, thereby suggesting no bottleneck effect due to repellent collar use.

10.1371/journal.pntd.0004303.t005

###### Differentiation measures (*Fst*) and testing (p-value) between different *Leishmania infantum* isolates according to the use of collar repellent and clinical manifestations.

![](pntd.0004303.t005){#pntd.0004303.t005g}

  Subsamples                                                                                                              Number of isolates   *F*st     p-value
  ----------------------------------------------------------------------------------------------------------------------- -------------------- --------- ---------
  **Effect of collar repellent. Comparison of isolates from 1978 to 1995 and 2005 to 2011 (years 1996--2004 excluded)**                                  
  P endemic area                                                                                                          11 / 12              0.0412    0.15
  AM endemic area                                                                                                         87 / 40              ≈ 0       0.95
  **Comparison of clinical manifestations. Other means VL, CL, MCL**                                                                                     
  AM AC vs other 1991--2001                                                                                               9 / 172              0.0763    0.10000
  AM AC vs HIV isolated from 1994 to 1998 in the same endemic area                                                        11 / 9               0.0830    0.10000
  HIV + vs HIV -                                                                                                          95 / 150             0.0683    0.05000
  HIV + vs VL adult                                                                                                       95 / 72              0.0857    0.05000
  HIV + vs CanL CatL                                                                                                      95 / 21              0.0167    0.50000
  P HIV + vs VL adult                                                                                                     40 / 11              0.0020    0.80000
  AM HIV + vs VL adult                                                                                                    52 / 50              0.1510    0.05000
  IVL vs CanL CatL                                                                                                        58 / 21              -0.0013   0.90000
  VL vs IVL                                                                                                               70 / 57              0.0003    0.30000

Nine isolates from asymptomatic carriers were compared with 11 isolates from HIV patients collected between 1994 and 1998 in the same restricted endemic area. To avoid bias, we selected isolates collected two years before and after the date of the collection of the asymptomatic carrier isolates (1996). Unlike the findings reported by Hide et al., no genetic differentiation was observed between isolates from asymptomatic carriers and those derived from HIV+ patients ([Table 5](#pntd.0004303.t005){ref-type="table"}) \[[@pntd.0004303.ref009]\]. However, additional isolates from asymptomatic carriers are required to strengthen these findings. A genetic differentiation was observed between isolates from HIV+ and VL adult patients in AM ([Table 5](#pntd.0004303.t005){ref-type="table"}).

Clustering analysis {#sec015}
-------------------

Bayesian model-based analysis of the 270 isolates using STRUCTURE (with calculation of ΔK) indicated two distinct genetic populations ([Fig 5A](#pntd.0004303.g005){ref-type="fig"}). Population A consisted of 148 samples: 73 from P, 61 from AM, seven from CO and seven from CE. This population consisted of zymodemes MON-1 and nine isolates with zymodemes other than MON-1. Population B consisted of 109 isolates: 104 from AM, two from P, two from CO and one from CE. Isolates from Population B were all characterized zymodeme MON-1. Among the Populations A and B, 13 isolates had mixed genotypes (11 isolates corresponding to seven genotypes and two isolates corresponding to two genotypes in Populations A and B, respectively). The isolates with mixed genotypes shared allele characteristics of each population. All isolates with mixed genotypes were collected in the AM endemic area and were characterized zymodeme MON-1. Thus, Population A is a mixed population with almost an equivalent number of isolates from AM and P corresponding to MON-1 and all non-MON-1 isolates. The estimated gene flow between isolates from AM and P within Population A (*N*m value) was 8.38. Population A also displayed a marked proportion of isolates from HIV+ patients (44.7%) compared with Population B (21.6%) (p\<0.05). The two populations A and B defined by STRUCTURE were significantly different as shown by the *F*st value 0.503 and p-value equal to 0.05. The estimated gene flow between the populations (*N*m value) was 0.25, thereby indicating very few exchanges between those two populations.

![Estimated population structure for *L*. *infantum* from Southeastern France assessed using STRUCTURE software based on the analysis of the 270 *L*. *infantum* DNA samples at 12 microsatellite markers.\
**A**: The plots show the estimated membership coefficient (Q) of each isolates. Each isolate is represented by a single vertical line divided into K colors, in which K is the number of populations assumed. Each color represents one population, and the length of the colored segment shows the estimated proportion of isolates membership in that population. The derived graph for delta K shows K = 2, thereby indicating the presence of two populations in the investigated sample set. **B**: Isolates of the sub-populations A and B with delta K values for each sub-population. Two close values were observed for K in sub-population A: K = 4 and K = 6. For sub-population B, K = 2.](pntd.0004303.g005){#pntd.0004303.g005}

The STRUCTURE analysis of Population A separately from Population B, excluding admixed isolates (13 isolates), revealed a delta K graph with two peaks at K = 4 and K = 6 ([Fig 5B](#pntd.0004303.g005){ref-type="fig"}). The main difference between K = 4 and K = 6 was that sub-population A1' at K = 4 was split into three populations at K = 6: sub-population A2 (four isolates from sub-population A1'), A3 (16 isolates from sub-population A1') and A4 (15 isolates from sub-population A1'). Whether at K = 4 or K = 6, the sub-population defined contained isolates from the AM and P endemic areas and from HIV+ patients. The non-MON-1 isolates were grouped into sub-population A1' and A3' with K = 4 and into sub-population A2, A4 and A6 with K = 6. No cluster based on clinical data, geographic area or zymodeme profile was found within the defined sub-populations. Some isolates displayed mixed genotypes within the A sub-populations. At K = 4 and K = 6, 26 and 44 isolates had mixed genotypes, respectively. At K = 6, isolates with mixed genotypes came from P (n = 33; 75%), AM (n = 8; 18.2%) and CE (n = 3; 6.8%).

When excluding mixed genotypes, the sub-populations A1, A2, A3, A4, A5 and A6 as well as A1', A2', A3' and A4' were significantly different, as shown by the significant *F*st values ranging from 0.249 to 0.833 and from 0.322 to 0.813 for K = 4 and K = 6, respectively ([Table 6](#pntd.0004303.t006){ref-type="table"}). At K = 4, the highest *Nm* value was obtained between sub-population A1' and sub-population A3' (0.53), whereas at K = 6, the highest *Nm* value was 0.75 between sub-population A2 and sub-population A6, thereby indicating only limited genotype flow between these sub-populations ([Table 6](#pntd.0004303.t006){ref-type="table"}).

10.1371/journal.pntd.0004303.t006

###### Differentiation measures, migration rate and statistical significance between different *Leishmania infantum* isolates according to sub-populations defined using STRUCTURE.

In sub populations A, the isolates with mixed genotypes have been excluded (26 and 44 isolates for K = 4 and K = 6, respectively). Only the highest and lowest *F*st values are represented in this table.

![](pntd.0004303.t006){#pntd.0004303.t006g}

              Sub populations   Number of Isolates   *F*st   *p*-value   *Nm*
  ----------- ----------------- -------------------- ------- ----------- ------
  Sub Pop A   Pop A2' vs A4'    26 / 30              0.813   0.008       0.06
  K = 4       Pop A1' vs A3'    52 / 14              0.322   0.008       0.53
  Sub Pop A   Pop A3 vs A5      16 / 26              0.833   0.003       0.05
  K = 6       Pop A2 vs A6      7 / 13               0.249   0.003       0.75
  Sub Pop B                                                              
  K = 2       Pop B1 vs B2      51 / 58              0.537   0.050       0.22

*F*st: degree of genetic differentiation, *Nm*: migration rates, *p*-value: statistical significance.

Two main sub-populations were defined using STRUCTURE for Population B: sub-population B1 and sub-population B2. No mixed genotypes were present. Sub-population B1 consisted of 48 isolates from AM, two from P and one from CO. Sub-population B2 consisted of 56 isolates from AM, one from CO and one from CE. These two sub-populations were genetically different as evidenced by the *F*st value (0.537 and *p*-value = 0.05). Few exchanges occurred between these two sub-populations (*Nm* = 0.22 was obtained between sub-population B1 and sub-population B2).

Sub-populations A3' (sub-population A K = 4) and A6 (sub-population A K = 6) displayed the highest number of alleles per population ([Table 7](#pntd.0004303.t007){ref-type="table"}). The expected heterozygosity (*He*), a measure of genetic diversity, was higher in the A sub-populations with non-MON-1 isolates compared with the A sub-populations with only MON-1 isolates ([Table 7](#pntd.0004303.t007){ref-type="table"}). All A sub-populations displayed a high inbreeding coefficient (*F*~IS~) (\> 0.7), whereas the sub-population B2 displayed a low inbreeding coefficient (0.343) ([Table 7](#pntd.0004303.t007){ref-type="table"}).

10.1371/journal.pntd.0004303.t007

###### Descriptive statistics per population.

![](pntd.0004303.t007){#pntd.0004303.t007g}

              Name of the sub population   n    *Na*    *He*    *Ho*     *F*~IS~
  ----------- ---------------------------- ---- ------- ------- -------- ---------
  Sub Pop A   Pop A1'                      52   3.500   0.380   0.066    0.830
  K = 4       Pop A2'                      26   1.500   0.052   0.013    0.763
              Pop A3'                      14   5.417   0.695   0.048    0.936
              Pop A4'                      30   2.000   0.161   0.014    0.917
  Sub Pop A   Pop A1                       27   1.917   0.149   0.012    0.920
  K = 6       Pop A2                       7    2.417   0.395   0.071    0.843
              Pop A3                       16   1.917   0.169   0.016    0.913
              Pop A4                       15   1.917   0.184   0.006    0.972
              Pop A5                       26   1.500   0.052   0.013    0.763
              Pop A6                       13   5.000   0.680   0.051    0.931
  Sub Pop B   Pop B1                       51   1.500   0.080   0.011    0.860
  K = 2       Pop B2                       58   1.917   0.067   0.0445   0.34337

In sub populations A, the isolates with mixed genotypes have been excluded (26 and 44 isolates for K = 4 and K = 6, respectively). n: number of isolates per population; *Na*: number of alleles; *Ho*: observed heterozygosity; *He*: expected heterozygosity; *F*~IS~: inbreeding coefficient.

The NJ tree presented in [Fig 6](#pntd.0004303.g006){ref-type="fig"} provides a graphic representation of the data. The bootstrap values based on the re-sampling of loci were low and therefore not included in the NJ tree ([Fig 6](#pntd.0004303.g006){ref-type="fig"}). This was due to the presence of admixed genotypes and the high number of shared alleles even if the allelic frequencies are different between the populations and sub-populations. Two main clusters were found to correspond to the two populations obtained using STRUCTURE at K = 2. Population B formed a separate cluster from Population A. The two sub-clusters defined using STRUCTURE for Populations B1 and B2 are shown on the NJ tree. However, for Population A, the clusters defined by the NJ tree did not perfectly correlate with the A sub-populations defined using STRUCTURE for neither K = 4 nor K = 6. The sub-populations A1, A2 and A3 (A1: four genotypes from AM and seven genotypes from P; A2: one genotype from AM, one from CO and three from P; and A3: eight genotypes from AM, two from P and one from CO) are dispersed throughout the NJ tree. Within Population A, the isolates from AM and P are dispersed throughout the cluster with no correlation with endemic area, clinical form or host background. The mixed genotypes were present between the two main clusters of Populations A and B as well as within the cluster of A sub-populations. Some non-MON-1 isolates grouped together as a paraphyletic group in the sub-population A6, while the others were dispersed among the MON-1 isolates and are present at the end of the branches. As previously described, the MON-108 isolate is closely related to the MON-1 isolates \[[@pntd.0004303.ref023]--[@pntd.0004303.ref025]\]. Regarding the nine isolates from AC, two (genotype 21) were present in sub-population A5, whereas seven (genotype 43) belonged to sub-population B1 and grouped with isolates from infant VL and HIV + VL patients. None of the isolates from AC has a mixed genotype. Samples isolated from CanL grouped together with human isolates, and no correlation was found between host and MLMT profile.

![Unrooted neighbor-joining tree inferred from genetic distances derived from the proportion of alleles shared among the 270 isolates of *L*. *infantum* based on 12 microsatellite markers.\
The two populations defined using STRUCTURE are highlighted. The blue stars correspond to the non-MON-1 strains. At the end of each branche of the network, the first three characters correspond to the arbitrarily assigned number for each genotype, the following two characters (AM, P, Ce, Co) correspond to the endemic area of sample collection, and then the last two characters correspond to the number of isolates with the given genotype. The orange rectangles represent the isolates with mixed genotypes. The sub populations are represented with colored ovals at K = 6 for A sub-populations and K = 2 for B sub-populations. The isolates with no color are those with mixed genotypes within A sub-populations at K = 6. MEGA 4 software was used to visualize the neighbor-joining tree.](pntd.0004303.g006){#pntd.0004303.g006}

Discussion {#sec016}
==========

Leishmaniasis due to *L*. *infantum* is endemic in Southern France. In this study, we used MLMT, a molecular tool useful for population genetic studies, to analyze an extensive set of isolates from four endemic areas in Southern France (AM, P, CE and CO). To the best of our knowledge, this study is the first to investigate a large number of *L*. *infantum* isolates from different endemic areas in Southern France. We also focused on the AM and P endemic areas over an extended period of time. A greater number of samples came from AM than P (AM = 178 versus P = 75) because AM is the most active foci in France with the greatest number of leishmaniasis cases per year \[[@pntd.0004303.ref002]\]. The study period was also longer for the AM area than for the P endemic area (AM: 1978--2011; P: 1993--2009). This aspect may generate a sampling bias, although no significant genetic differentiation was found when comparing isolates from AM and P during the same time period. Although MON-1 is the most prevalent zymodeme, other zymodemes also circulate in the south of France \[[@pntd.0004303.ref007]\]. Microsatellite characterization of *L*. *infantum* isolates revealed a total of 121 different genotypes. Overall, 91 unique genotypes and 30 repeated genotypes were found. A greater number of repeated genotypes were observed in AM compared with P for the same period, thereby suggesting variations in the transmission cycle between the two areas such as outbreak, vector diversity or density, or host density.

In the AM endemic area, the isolates belonged to two main populations as defined by STRUCTURE: Population A and Population B. Within Population A, gene flow occurred between the AM and P endemic areas. The spread of isolates seems to be from AM to P, as indicated by the results of genotype 21, which was found 15 years later in P.

Substantial genetic diversity was found to be comparable to other endemic areas, even within zymodeme MON-1, thereby confirming previous analyses assessed by other markers \[[@pntd.0004303.ref026]\]. As genetic differentiation depends on the area, our findings suggest strong epidemiological structuring. This is in agreement with the known mechanism of *Leishmania* transmission and spread in micro-foci and the entomologic data that have demonstrated limited sandfly dispersion \[[@pntd.0004303.ref027]--[@pntd.0004303.ref031]\]. Indeed, considering the behavior of the phlebotomine sandfly, it seems less likely that the spread of isolates from AM to P is due to sandfly movement \[[@pntd.0004303.ref032]\]. Unfortunately, due to the small sample size of the phlebotomine sandfly isolates, we cannot investigate the transmission between sandflies, humans and canine hosts in further detail. We suspect that people traveling with their infected dogs between the endemic areas plays a possible role in the etiology of these exchanges. This has been already described for the emergence of *L*. *infantum* in South America probably via Conquistadores infected dogs from Portugal \[[@pntd.0004303.ref033]\]. More recently, an intercontinental transportation from France to French Guiana was also reported due to the probable importation of *L*. *infantum* from an infected dog \[[@pntd.0004303.ref034]\]. Notably, some repeated genotypes in the AM endemic area are well settled and continue to spread through the area over time. Indeed, some repeated genotypes were detected during a limited period, ranging from 6 to 15 years, and are no longer detected (genotypes 36, 43, 46, 53, 68 and 77). However, other genotypes were still detected in 2011 (genotypes 34, 55 and 57) and one genotype spread to P endemic area (genotype 21). The mixed genotypes between Population A and Population B were isolated in the AM endemic area, whereas in the A sub-populations, 75% of the mixed genotypes came from the P endemic area. We also observed a predominance of isolates from HIV+ patients in Population A (44.7%) compared with Population B (21.6%), which may indicate a variation in virulence. Indeed, these isolates from HIV+ patients may produce leishmaniasis in immunocompromised patients, whereas affected immunocompetent patients may develop only an asymptomatic infection \[[@pntd.0004303.ref035]\]. This hypothesis is in agreement with the distribution of isolates from AC in both Population A and Population B. These isolates belonged to the genotypes 21 (2 AC) and 43 (7 AC), with samples from HIV+ VL, IVL, VL and CanL cases and samples from infant VL and HIV+ VL patients, respectively. The comparison of isolates from AC and those from HIV+ patients isolated during the same period and within the same restricted endemic area revealed no genetic differentiation between these populations. This finding contrasts with previous data reported by Hide et al. \[[@pntd.0004303.ref009]\] and as suspected, does not reflect a difference in virulence. However, further isolates from asymptomatic carriers must be assessed to confirm our hypotheses. This is critical in the endemic areas of Southern France (as well as all endemic foci of leishmaniasis), where the isolates responsible for leishmaniasis represent only the tip of the iceberg \[[@pntd.0004303.ref036]\]. Indeed, depending on the test used to detect asymptomatic carriage, prevalence varies from 30% to 46.8% in the AM endemic area \[[@pntd.0004303.ref036]\]. Although our study provides important insight into leishmaniasis epidemiology in AM and P, our panel represents only a small proportion of the *L*. *infantum* population circulating in Southern France as samples from asymptomatic carriers, dogs and sandflies are underrepresented.

Microsatellite analyses may be useful to estimate relapse and re-infection rates, which is important to evaluate anti-*Leishmania* drug efficacy and transmission dynamics, respectively. This aspect is particularly important for the follow-up of patient treatment. MLMT may also be a useful tool to differentiate between relapses from re-infection cases \[[@pntd.0004303.ref011],[@pntd.0004303.ref025],[@pntd.0004303.ref026],[@pntd.0004303.ref035],[@pntd.0004303.ref037],[@pntd.0004303.ref038]\]. Moreover, Bourgeois et al. have described "active chronic visceral leishmaniasis" in patients with several episodes of VL \[[@pntd.0004303.ref020]\]. In this particular form of the disease, identifying the MLMT profile of each isolate responsible of each episode of VL could be useful to monitor and optimize treatment regimes. In our study, we detected probable treatment failure in HIV+ and non-HIV patients, as the MLMT profiles were indistinguishable from one episode to another. Certain patients likely experienced re-infection, as isolates from two different episodes of leishmaniasis in same patient displayed different MLMT profiles. However, we cannot exclude the possibility of a mixed infection with differential strain isolation depending on the time of sampling. Due to the small number of patients with isolates from several biological samples at different times, the rate of relapse and re-infection needs to be confirmed on a larger sample set. Thus, the results on relapse and re-infection should be interpreted with caution. Further investigations are required to assess these hypotheses in further detail.

The high ratio of repeated genotypes in HIV patients (81.6%) compared with the remaining population (41%) may be due to an outbreak amongst this fragile human population. Outbreaks have already been reported among intravenous drug users, a population also frequently affected by HIV infection \[[@pntd.0004303.ref039],[@pntd.0004303.ref040]\]. Nevertheless, we have no information concerning this aspect of the case population in our study.

Faucher et al. have highlighted the heterogeneity of environments associated with VL transmission in Southeastern France \[[@pntd.0004303.ref005]\]. The authors showed two distinct foci strongly associated with specific environments. One focus, corresponding to the AM endemic area, was characterized by scattered habitation and mixed forest in the foothills. In contrast, the other focus in the P endemic area was centered in urban areas of Marseille. These environmental differences correlate with the strong genetic differentiation we found between the *Leishmania* populations from AM and P. Indeed, the ecosystem influences the transmission cycle and thus the population dynamics of parasites. Moreover, in the P endemic area, Toscana virus, which is responsible for summer meningitis, and *L*. *infantum* share the same vector, *Phlebotomus perniciosus*. A recent study has described dogs co-infected by these two organisms \[[@pntd.0004303.ref041]\]. Although cases of co-infection in humans or vectors have not been reported, we suspect that is also possible. This phenomenon of co-infection may have an impact on *Leishmania* transmission and should be addressed in future studies to understand whether this may also influence parasite evolution.

Other wild reservoirs of *L*. *infantum* have been demonstrated in Europe such as fox, rats and hare \[[@pntd.0004303.ref042]\]. These wild reservoirs are able to transmit *L*. *infantum* to sandflies. However, the isolates from wild reservoirs have indistinguishable genotypes from those derived from domestic dogs and humans \[[@pntd.0004303.ref026],[@pntd.0004303.ref043]\]. No isolates from wild animals were included in our study. The only uncommon host included in our study was a cat, and the isolate from this animal shared the genotype 55 with isolates from dog, IVL, HIV+ VL and VL samples.

In some studies, the isolates with a zymodeme other than MON-1 grouped together either via neighbor joining tree or STRUCTURE analysis \[[@pntd.0004303.ref025],[@pntd.0004303.ref026]\]. We did not find such correlations with our data which is probably due to the high number of strains with mixed genotypes. Indeed the nine non-MON-1 isolates did not group into a separate population but rather clustered into Population A with a majority of the MON-1 isolates. In the NJ tree, some non-MON-1 isolates appeared as a paraphyletic group, while others were either isolated or dispersed among other zymodemes \[[@pntd.0004303.ref023]--[@pntd.0004303.ref025]\]. The zymodeme MON-108 (genotype 92) isolate appeared very close to MON-1 isolates with the genotype 37 \[[@pntd.0004303.ref023]--[@pntd.0004303.ref025]\].

In our study, no correlation was found between MLMT profile, clinical expression of the disease, immune status and host. Finally, MLMT is more discriminant and thus more appropriate than MLEE to evaluate epidemiological changes among parasite population in Southern France. MLMT data provided a better understanding of gene flow between *L*. *infantum* populations within the Southeastern France endemic area.

Supporting Information {#sec017}
======================

###### Designation, characteristics and MLMT profiles of the *Leishmania infantum* isolates used in this study.

AM: Alpes-Maritimes; P: Provence; CE: Cévennes; CO: Corsica. VL--Visceral leishmaniasis; IVL--Infant under 15 years visceral leishmaniasis; CL--Cutaneous leishmaniasis; MCL--Muco-cutaneous leishmaniasis; RVL---New episode of leishmaniasis in patients; AC--Asymptomatic carrier; CanL--Canine leishmaniasis; CatL--Leishmaniasis in cat; PHLE: isolate from phlebotomine sandfly; UK--Unknown. n. d. = not defined.

(XLS)

###### 

Click here for additional data file.
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